Risk Assessment in Stage II Colon Cancer
In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer from different angles.
Risk Assessment in Stage II Colon Cancer
This supplement and associated publication costs were funded by Genomic Health.
Over the past years, our understanding of stage II colon cancer has made significant advances leading to a refinement in the identification of the patient population and the treatment options considered appropriate as adjuvant therapy in this setting. In this supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer.
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
